Clinical Trial Update: Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating sorafenib for advanced renal cell carcinoma has completed, outlining the treatment protocol used in this patient population.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Phase 3 | Status: COMPLETED